At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 43 enrolled
Drug / intervention
Ramucirumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
In Brief
A Phase 2 clinical trial evaluating Ramucirumab and Somatostatin Analog for Carcinoid Tumors. Completed, enrolled 43 participants across 2 sites.
Detailed Summary
This research study is evaluating the drug Ramucirumab as a possible treatment for Advanced, Progressive Carcinoid Tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoid Tumors
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartJun 2016
Primary CompletionDec 2022
Study CompletionDec 2023
TodayJul 2026
First PostedJun 10, 2016
Enrollment StartJun 14, 2016
Primary CompletionDec 31, 2022
Study CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 10.1 years ago
Interventions
Ramucirumabdrug
Somatostatin Analogdrug